{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,29]],"date-time":"2026-06-29T10:46:29Z","timestamp":1782729989753,"version":"3.54.5"},"reference-count":39,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2021,2,1]],"date-time":"2021-02-01T00:00:00Z","timestamp":1612137600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2021,2,16]],"date-time":"2021-02-16T00:00:00Z","timestamp":1613433600000},"content-version":"vor","delay-in-days":15,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100000002","name":"U.S. Department of Health\n& Human Services | National Institutes of Health","doi-asserted-by":"publisher","award":["Intramural Research\nProgram"],"award-info":[{"award-number":["Intramural Research\nProgram"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Exp Mol Med"],"published-print":{"date-parts":[[2021,2]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Synucleinopathies are age-related neurological disorders characterized\nby the progressive deposition of \u03b1-synuclein (\u03b1-syn) aggregates and\ninclude Parkinson\u2019s disease (PD) and dementia with Lewy bodies (DLB).\nAlthough cell-to-cell \u03b1-syn transmission is thought to play a key role in\nthe spread of \u03b1-syn pathology, the detailed mechanism is still unknown.\nNeuroinflammation is another key pathological feature of synucleinopathies. Previous\nstudies have identified several immune receptors that mediate neuroinflammation in\nsynucleinopathies, such as Toll-like receptor 2 (TLR2). However, the species of\n\u03b1-syn aggregates varies from study to study, and how different \u03b1-syn\naggregate species interact with innate immune receptors has yet to be addressed.\nTherefore, we investigated whether innate immune receptors can facilitate the uptake\nof different species of \u03b1-syn aggregates. Here, we examined whether\nstimulation of TLRs could modulate the cellular uptake and degradation of\n\u03b1-syn fibrils despite a lack of direct interaction. We observed that\nstimulation of TLR2 in vitro accelerated \u03b1-syn fibril uptake in neurons and\nglia while delaying the degradation of \u03b1-syn in neurons and astrocytes.\nInternalized \u03b1-syn was rapidly degraded in microglia regardless of whether\nTLR2 was stimulated. However, cellular \u03b1-syn uptake and degradation kinetics\nwere not altered by TLR4 stimulation. In addition, upregulation of TLR2 expression\nin a synucleinopathy mouse model increased the density of Lewy-body-like inclusions\nand induced morphological changes in microglia. Together, these results suggest that\ncell type-specific modulation of TLR2 may be a multifaceted and promising\ntherapeutic strategy for synucleinopathies; inhibition of neuronal and astroglial\nTLR2 decreases pathogenic \u03b1-syn transmission, but activation of microglial\nTLR2 enhances microglial extracellular \u03b1-syn clearance.<\/jats:p>","DOI":"10.1038\/s12276-021-00562-6","type":"journal-article","created":{"date-parts":[[2021,2,17]],"date-time":"2021-02-17T13:26:10Z","timestamp":1613568370000},"page":"281-290","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":40,"title":["RETRACTED ARTICLE: Effects of innate immune receptor stimulation on extracellular \u03b1-synuclein uptake and degradation by brain resident cells"],"prefix":"10.1038","volume":"53","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-9936-8195","authenticated-orcid":false,"given":"Changyoun","family":"Kim","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Somin","family":"Kwon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michiyo","family":"Iba","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brian","family":"Spencer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Edward","family":"Rockenstein","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Mante","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anthony","family":"Adame","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Soo Jean","family":"Shin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jerel A.","family":"Fields","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert A.","family":"Rissman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Seung-Jae","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eliezer","family":"Masliah","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,2,16]]},"reference":[{"key":"562_CR1","doi-asserted-by":"publisher","first-page":"92","DOI":"10.1038\/nrneurol.2013.275","volume":"10","author":"HJ Lee","year":"2014","unstructured":"Lee, H. J., Bae, E. J. & Lee, S. J. Extracellular\nalpha-synuclein\u2014a novel and crucial factor in Lewy body diseases.\nNat. Rev. Neurol.\n10, 92\u201398 (2014).","journal-title":"Nat. Rev. Neurol."},{"key":"562_CR2","doi-asserted-by":"publisher","first-page":"303","DOI":"10.1111\/j.1471-4159.2008.05612.x","volume":"107","author":"C Kim","year":"2008","unstructured":"Kim, C. & Lee, S. J. Controlling the mass action of\nalpha-synuclein in Parkinson\u2019s disease. J.\nNeurochem.\n107, 303\u2013316 (2008).","journal-title":"J. Neurochem."},{"key":"562_CR3","doi-asserted-by":"publisher","first-page":"S62","DOI":"10.1016\/S1353-8020(13)70017-8","volume":"20","author":"H McCann","year":"2014","unstructured":"McCann, H., Stevens, C. H., Cartwright, H. & Halliday, G.\nM. alpha-Synucleinopathy phenotypes. Parkinsonism Relat.\nDisord.\n20, S62\u2013S67 (2014).","journal-title":"Parkinsonism Relat. Disord."},{"key":"562_CR4","doi-asserted-by":"publisher","first-page":"1916","DOI":"10.1212\/01.wnl.0000312279.49272.9f","volume":"70","author":"H Braak","year":"2008","unstructured":"Braak, H. & Del Tredici, K. Invited Article: nervous system\npathology in sporadic Parkinson disease. Neurology\n70, 1916\u20131925 (2008).","journal-title":"Neurology"},{"key":"562_CR5","doi-asserted-by":"publisher","first-page":"1044","DOI":"10.1016\/j.neuron.2013.09.004","volume":"79","author":"JT Bendor","year":"2013","unstructured":"Bendor, J. T., Logan, T. P. & Edwards, R. H. The function\nof alpha-synuclein. Neuron\n79, 1044\u20131066 (2013).","journal-title":"Neuron"},{"key":"562_CR6","doi-asserted-by":"publisher","first-page":"547","DOI":"10.5607\/en.2019.28.5.547","volume":"28","author":"S Kwon","year":"2019","unstructured":"Kwon, S., Iba, M., Masliah, E. & Kim, C. Targeting\nmicroglial and neuronal Toll-like receptor 2 in synucleinopathies. Exp. Neurobiol.\n28, 547\u2013553 (2019).","journal-title":"Exp. Neurobiol."},{"key":"562_CR7","doi-asserted-by":"publisher","first-page":"1008","DOI":"10.3389\/fphar.2019.01008","volume":"10","author":"L Guzman-Martinez","year":"2019","unstructured":"Guzman-Martinez, L. et al. Neuroinflammation as a common feature of\nneurodegenerative disorders. Front. Pharm.\n10, 1008 (2019).","journal-title":"Front. Pharm."},{"key":"562_CR8","doi-asserted-by":"publisher","first-page":"158","DOI":"10.1016\/j.pneurobio.2018.06.010","volume":"169","author":"S Lim","year":"2018","unstructured":"Lim, S., Kim, H. J., Kim, D. K. & Lee, S. J.\nNon-cell-autonomous actions of alpha-synuclein: implications in glial\nsynucleinopathies. Prog. Neurobiol.\n169, 158\u2013171 (2018).","journal-title":"Prog. Neurobiol."},{"key":"562_CR9","doi-asserted-by":"publisher","DOI":"10.1038\/ncomms2534","volume":"4","author":"C Kim","year":"2013","unstructured":"Kim, C. et al. Neuron-released oligomeric alpha-synuclein is an\nendogenous agonist of TLR2 for paracrine activation of microglia. Nat. Commun.\n4, 1562 (2013).","journal-title":"Nat. Commun."},{"key":"562_CR10","doi-asserted-by":"publisher","unstructured":"Kim, C. et al. LRRK2 mediates microglial neurotoxicity via NFATc2\nin rodent models of synucleinopathies. Sci. Transl.\nMed. 12\nhttps:\/\/doi.org\/10.1126\/scitranslmed.aay0399 (2020).","DOI":"10.1126\/scitranslmed.aay0399"},{"key":"562_CR11","doi-asserted-by":"publisher","first-page":"236","DOI":"10.1016\/j.bbi.2018.12.003","volume":"76","author":"M Campolo","year":"2019","unstructured":"Campolo, M. et al. TLR4 absence reduces neuroinflammation and\ninflammasome activation in Parkinson\u2019s diseases in vivo model. Brain Behav. Immun.\n76, 236\u2013247 (2019).","journal-title":"Brain Behav. Immun."},{"key":"562_CR12","doi-asserted-by":"publisher","first-page":"349","DOI":"10.1002\/glia.22437","volume":"61","author":"L Fellner","year":"2013","unstructured":"Fellner, L. et al. Toll-like receptor 4 is required for\nalpha-synuclein dependent activation of microglia and astroglia. Glia\n61, 349\u2013360 (2013).","journal-title":"Glia"},{"key":"562_CR13","doi-asserted-by":"publisher","first-page":"1503","DOI":"10.1038\/s41401-019-0280-2","volume":"40","author":"QH Shao","year":"2019","unstructured":"Shao, Q. H. et al. TLR4 deficiency has a protective effect in the\nMPTP\/probenecid mouse model of Parkinson\u2019s disease. Acta Pharm. Sin.\n40, 1503\u20131512 (2019).","journal-title":"Acta Pharm. Sin."},{"key":"562_CR14","doi-asserted-by":"publisher","first-page":"954","DOI":"10.1016\/j.ajpath.2011.04.013","volume":"179","author":"N Stefanova","year":"2011","unstructured":"Stefanova, N. et al. Toll-like receptor 4 promotes alpha-synuclein\nclearance and survival of nigral dopaminergic neurons. Am. J. Pathol.\n179, 954\u2013963 (2011).","journal-title":"Am. J. Pathol."},{"key":"562_CR15","doi-asserted-by":"publisher","unstructured":"Mao, X. et al. Pathological alpha-synuclein transmission initiated\nby binding lymphocyte-activation gene 3. Science\n353, https:\/\/doi.org\/10.1126\/science.aah3374 (2016).","DOI":"10.1126\/science.aah3374"},{"key":"562_CR16","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-017-08720-5","volume":"7","author":"E Ihse","year":"2017","unstructured":"Ihse, E. et al. Cellular internalization of alpha-synuclein\naggregates by cell surface heparan sulfate depends on aggregate conformation and\ncell type. Sci. Rep.\n7, 9008 (2017).","journal-title":"Sci. Rep."},{"key":"562_CR17","doi-asserted-by":"publisher","first-page":"1178","DOI":"10.1002\/glia.20532","volume":"55","author":"W Zhang","year":"2007","unstructured":"Zhang, W. et al. Microglial PHOX and Mac-1 are essential to the\nenhanced dopaminergic neurodegeneration elicited by A30P and A53T mutant\nalpha-synuclein. Glia\n55, 1178\u20131188 (2007).","journal-title":"Glia"},{"key":"562_CR18","doi-asserted-by":"publisher","unstructured":"Surguchev, A. A., Emamzadeh, F. N. & Surguchov, A. Cell\nresponses to extracellular alpha-synuclein. Molecules\n24, https:\/\/doi.org\/10.3390\/molecules24020305 (2019).","DOI":"10.3390\/molecules24020305"},{"key":"562_CR19","doi-asserted-by":"publisher","DOI":"10.1038\/emm.2014.6","volume":"46","author":"C Kim","year":"2014","unstructured":"Kim, C. et al. beta1-integrin-dependent migration of microglia in\nresponse to neuron-released alpha-synuclein. Exp. Mol.\nMed.\n46, e91 (2014).","journal-title":"Exp. Mol. Med."},{"key":"562_CR20","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0056891","volume":"8","author":"J Fields","year":"2013","unstructured":"Fields, J., Cisneros, I. E., Borgmann, K. & Ghorpade, A.\nExtracellular regulated kinase 1\/2 signaling is a critical regulator of\ninterleukin-1beta-mediated astrocyte tissue inhibitor of metalloproteinase-1\nexpression. PLoS ONE\n8, e56891 (2013).","journal-title":"PLoS ONE"},{"key":"562_CR21","doi-asserted-by":"publisher","first-page":"771","DOI":"10.1016\/j.celrep.2015.09.044","volume":"13","author":"C Kim","year":"2015","unstructured":"Kim, C. et al. Antagonizing neuronal Toll-like receptor 2 prevents\nsynucleinopathy by activating autophagy. Cell\nRep.\n13, 771\u2013782 (2015).","journal-title":"Cell Rep."},{"key":"562_CR22","doi-asserted-by":"publisher","first-page":"1888","DOI":"10.1523\/JNEUROSCI.3809-03.2004","volume":"24","author":"HJ Lee","year":"2004","unstructured":"Lee, H. J., Khoshaghideh, F., Patel, S. & Lee, S. J.\nClearance of alpha-synuclein oligomeric intermediates via the lysosomal\ndegradation pathway. J. Neurosci.\n24, 1888\u20131896 (2004).","journal-title":"J. Neurosci."},{"key":"562_CR23","doi-asserted-by":"publisher","DOI":"10.1038\/srep30891","volume":"6","author":"C Kim","year":"2016","unstructured":"Kim, C. et al. Exposure to bacterial endotoxin generates a distinct\nstrain of alpha-synuclein fibril. Sci. Rep.\n6, 30891 (2016).","journal-title":"Sci. Rep."},{"key":"562_CR24","doi-asserted-by":"publisher","first-page":"1265","DOI":"10.1126\/science.287.5456.1265","volume":"287","author":"E Masliah","year":"2000","unstructured":"Masliah, E. et al. Dopaminergic loss and inclusion body formation\nin alpha-synuclein mice: implications for neurodegenerative disorders. Science\n287, 1265\u20131269\n(2000).","journal-title":"Science"},{"key":"562_CR25","doi-asserted-by":"publisher","first-page":"1753","DOI":"10.1038\/mt.2014.129","volume":"22","author":"B Spencer","year":"2014","unstructured":"Spencer, B. et al. ESCRT-mediated uptake and degradation of\nbrain-targeted alpha-synuclein single chain antibody attenuates neuronal\ndegeneration in vivo. Mol. Ther.\n22, 1753\u20131767 (2014).","journal-title":"Mol. Ther."},{"key":"562_CR26","doi-asserted-by":"publisher","DOI":"10.1186\/s12974-015-0455-9","volume":"12","author":"C Kim","year":"2015","unstructured":"Kim, C. et al. Hypoestoxide reduces neuroinflammation and\nalpha-synuclein accumulation in a mouse model of Parkinson\u2019s disease.\nJ. Neuroinflamm.\n12, 236 (2015).","journal-title":"J. Neuroinflamm."},{"key":"562_CR27","doi-asserted-by":"publisher","first-page":"423","DOI":"10.1016\/j.bbrc.2008.05.045","volume":"372","author":"HJ Lee","year":"2008","unstructured":"Lee, H. J., Suk, J. E., Bae, E. J. & Lee, S. J. Clearance\nand deposition of extracellular alpha-synuclein aggregates in microglia.\nBiochem. Biophys. Res. Commun.\n372, 423\u2013428 (2008).","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"562_CR28","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1186\/s13024-018-0276-2","volume":"13","author":"C Kim","year":"2018","unstructured":"Kim, C. et al. Immunotherapy targeting Toll-like receptor 2\nalleviates neurodegeneration in models of synucleinopathy by modulating\nalpha-synuclein transmission and neuroinflammation. Mol.\nNeurodegener.\n13, 43 (2018).","journal-title":"Mol. Neurodegener."},{"key":"562_CR29","doi-asserted-by":"publisher","first-page":"303","DOI":"10.1007\/s00401-016-1648-8","volume":"133","author":"N Dzamko","year":"2017","unstructured":"Dzamko, N. et al. Toll-like receptor 2 is increased in neurons in\nParkinson\u2019s disease brain and may contribute to alpha-synuclein\npathology. Acta Neuropathol.\n133, 303\u2013319 (2017).","journal-title":"Acta Neuropathol."},{"key":"562_CR30","doi-asserted-by":"publisher","first-page":"591","DOI":"10.1016\/j.bbi.2018.02.012","volume":"69","author":"P La Vitola","year":"2018","unstructured":"La Vitola, P. et al. Alpha-synuclein oligomers impair memory\nthrough glial cell activation and via Toll-like receptor 2. Brain Behav. Immun.\n69, 591\u2013602 (2018).","journal-title":"Brain Behav. Immun."},{"key":"562_CR31","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1038\/nrn3406","volume":"14","author":"HA Lashuel","year":"2013","unstructured":"Lashuel, H. A., Overk, C. R., Oueslati, A. & Masliah, E.\nThe many faces of alpha-synuclein: from structure and toxicity to therapeutic\ntarget. Nat. Rev. Neurosci.\n14, 38\u201348 (2013).","journal-title":"Nat. Rev. Neurosci."},{"key":"562_CR32","doi-asserted-by":"publisher","first-page":"13010","DOI":"10.1073\/pnas.0903691106","volume":"106","author":"P Desplats","year":"2009","unstructured":"Desplats, P. et al. Inclusion formation and neuronal cell death\nthrough neuron-to-neuron transmission of alpha-synuclein. Proc. Natl Acad. Sci. USA\n106, 13010\u201313015\n(2009).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"562_CR33","doi-asserted-by":"publisher","first-page":"42","DOI":"10.1186\/1750-1326-7-42","volume":"7","author":"KM Danzer","year":"2012","unstructured":"Danzer, K. M. et al. Exosomal cell-to-cell transmission of alpha\nsynuclein oligomers. Mol. Neurodegener.\n7, 42 (2012).","journal-title":"Mol. Neurodegener."},{"key":"562_CR34","doi-asserted-by":"publisher","first-page":"715","DOI":"10.1172\/JCI43366","volume":"121","author":"C Hansen","year":"2011","unstructured":"Hansen, C. et al. alpha-Synuclein propagates from mouse brain to\ngrafted dopaminergic neurons and seeds aggregation in cultured human cells.\nJ. Clin. Investig.\n121, 715\u2013725 (2011).","journal-title":"J. Clin. Investig."},{"key":"562_CR35","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-019-42399-0","volume":"9","author":"K Kakuda","year":"2019","unstructured":"Kakuda, K. et al. Ultrasonication-based rapid amplification of\nalpha-synuclein aggregates in cerebrospinal fluid. Sci.\nRep.\n9, 6001 (2019).","journal-title":"Sci. Rep."},{"key":"562_CR36","doi-asserted-by":"publisher","first-page":"423","DOI":"10.1007\/s11481-019-09835-4","volume":"14","author":"S Manne","year":"2019","unstructured":"Manne, S. et al. Ultrasensitive detection of aggregated\nalpha-synuclein in glial cells, human cerebrospinal fluid, and brain tissue\nusing the RT-QuIC assay: new high-throughput neuroimmune biomarker assay for\nParkinsonian disorders. J. Neuroimmune Pharm.\n14, 423\u2013435 (2019).","journal-title":"J. Neuroimmune Pharm."},{"key":"562_CR37","doi-asserted-by":"publisher","unstructured":"Guerrero-Ferreira, R. et al. Cryo-EM structure of alpha-synuclein\nfibrils. Elife\n7, https:\/\/doi.org\/10.7554\/eLife.36402 (2018).","DOI":"10.7554\/eLife.36402"},{"key":"562_CR38","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1016\/j.conb.2020.01.014","volume":"61","author":"R Guerrero-Ferreira","year":"2020","unstructured":"Guerrero-Ferreira, R., Kovacik, L., Ni, D. & Stahlberg, H.\nNew insights on the structure of alpha-synuclein fibrils using cryo-electron\nmicroscopy. Curr. Opin. Neurobiol.\n61, 89\u201395 (2020).","journal-title":"Curr. Opin. Neurobiol."},{"key":"562_CR39","doi-asserted-by":"publisher","first-page":"977","DOI":"10.1007\/s00401-020-02157-3","volume":"139","author":"A Van der Perren","year":"2020","unstructured":"Van der Perren, A. et al. The structural differences between\npatient-derived alpha-synuclein strains dictate characteristics of\nParkinson\u2019s disease, multiple system atrophy and dementia with Lewy\nbodies. Acta Neuropathol.\n139, 977\u20131000 (2020).","journal-title":"Acta Neuropathol."}],"updated-by":[{"DOI":"10.1038\/s12276-026-01789-x","type":"retraction","label":"Retraction","source":"publisher","updated":{"date-parts":[[2026,6,29]],"date-time":"2026-06-29T00:00:00Z","timestamp":1782691200000}}],"container-title":["Experimental &amp; Molecular Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s12276-021-00562-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s12276-021-00562-6","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s12276-021-00562-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,29]],"date-time":"2026-06-29T10:07:04Z","timestamp":1782727624000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s12276-021-00562-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,2]]},"references-count":39,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2021,2]]}},"alternative-id":["562"],"URL":"https:\/\/doi.org\/10.1038\/s12276-021-00562-6","relation":{},"ISSN":["1226-3613","2092-6413"],"issn-type":[{"value":"1226-3613","type":"print"},{"value":"2092-6413","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,2]]},"assertion":[{"value":"6 July 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 December 2020","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 December 2020","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 February 2021","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 June 2026","order":6,"name":"change_date","label":"Change Date","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Correction","order":7,"name":"change_type","label":"Change Type","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"This article has been retracted. Please see the Retraction Notice for more detail:","order":8,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"https:\/\/doi.org\/10.1038\/s12276-026-01789-x","URL":"https:\/\/doi.org\/10.1038\/s12276-026-01789-x","order":9,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"S.-J.L. is a founder and CEO of Neuramedy Co., Ltd.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}